

## Work plan for the South East London Integrated Medicines Optimisation Committee (SEL IMOC) – 2023/24

The following pages set out the work plan for the SEL IMOC from April 2023 – March 2024. Timescales for some of the work plan areas have been updated in September 2023, following a review of progress in quarters 1 and 2

**Given continuing pressures on the NHS, the intention is for this work plan to remain flexible and responsive to the changing environment.**

Delivery of the IMOC work plan is shared across member organisations, with each taking on leadership for a particular element of the work plan. The IMOC work plan aims to continue to provide clinical leadership, encourage collaboration and support QIPP delivery at borough level.

### Other IMOC outputs and ongoing work

It should be noted that **the Committee operates across the local healthcare system on a broad range of areas** – the Committee's work is **not limited** to the focused workstreams identified in this work plan. Other examples of work areas for the Committee include:

- Managing the entry of new medicines into the local healthcare system
- Development of treatment pathways/guidelines
- Horizon scanning through sub-groups to help plan for new medicines/indications
- Co-ordination, contributing and responding to national initiatives (for example, NICE guidance, RMOC guidance and NHSE initiatives)
- Development of shared care guidelines/Transfer of Prescribing
- Routine updates to existing pathways through IMOC sub-groups.

Additionally, there are workstreams that continue to be progressed in 23/24, for example:

- There are numerous pathway groups under the IMOC which continue to develop, update and review existing pathways throughout the year to ensure these are operating in line with the current evidence, including NICE technology appraisal guidance. The pathways ensure that all member organisations are given full opportunity to be aware of and be involved in the pathway / therapeutic area. A summary of the current pathway groups reporting to the IMOC can be found at the end of this work plan. For each pathway area, one SEL borough will be designated as the lead borough and be responsible for progressing the pathway within agreed timescales. A supporting borough will also be identified where this is considered necessary.
- Development of treatment pathways for the management of headache disorders in primary and secondary care.
- Work to explore the barriers to prescribing of long-acting antipsychotics in mental health led by SLaM with support from Lewisham, Southwark and Lambeth boroughs. Pilots are being planned for 23/24.
- Shared care task and finish group to continue to progress work to update processes for developing and implementing shared care guidance.
- Implementation of best value biologics will continue to be considered through the rheumatology, IBD and dermatology sub-groups.
- Work to rationalise the use of paediatric unlicensed specials across the healthcare system.
- Implementation of the NHSE Low priority medicines initiative/self-care topics as new and updated guidance is issued by NHS England.
- There have been a considerable number of guidelines and pathways ratified through the IMOC since its inception and a number of these will be due for review over the next year.

Update on progress in delivering the IMOC work plan will be noted on a quarterly basis at the IMOC meetings.

### Focused work plan areas for 2023/24

Clinical Area	Outcomes	Rationale for area	Impact anticipated from this work	Timescale for completion – updated in September 2023	Lead organisation and supporting (where required)
Ophthalmology – dry eyes	Development of local guidance to support best practice prescribing in dry eye conditions (to be adapted from the pan-London guidance)	South East London are outliers in prescribing of these agents. Prescribing of products for dry eyes is also an area of high financial impact for the local healthcare system.	<ul style="list-style-type: none"> <li>Consistent advice on when self-care is appropriate</li> <li>Consistent advice on product choice based on clinical and cost effectiveness across the local healthcare system</li> <li>Educational resource for primary care.</li> </ul>	October 2023 (previously July 2023)	<b>Lead:</b> Greenwich borough <b>Support:</b> Southwark/GSTT
Women's health	Development of a menopause treatment pathway	Establishing a treatment pathway would support a consistent approach to managing women undergoing menopause. There are documented inequalities ( <a href="#">BJGP</a> , <a href="#">DHSC strategy</a> ) in this area. This work will be progressed in collaboration with the Acute Provider Collaborative's gynaecology network.	<ul style="list-style-type: none"> <li>Consistent treatment pathway for SEL with advice on product choice and support in situations where there are stock shortages.</li> <li>Educational resource for primary care.</li> </ul>	November 2023 (previously August 2023)	<b>Lead:</b> Southwark borough/GSTT/ Acute Provider Collaborative gynaecology network <b>Support:</b> Lewisham borough
Mental Health	Resource to support and signpost primary care for reviewing the use of antidepressants in people with depression and to support their withdrawal where it is clinically appropriate to do so. There is an option to consider delivering this in partnership with the Clinical Effectiveness (CE) SEL programme as a CESEL Guide for Depression and Anxiety is planned in 23/24.	This is an area of dependence, risk and potential overprescribing, especially in people who continue treatment despite a poor response. Antidepressant prescribing is one of the focus areas within a <a href="#">national framework</a> aimed at optimising personalised care for adults prescribed these medicines.	<ul style="list-style-type: none"> <li>Patient safety benefits</li> <li>Educational resource for primary care.</li> </ul>	November 2023 (previously October 2023)	<b>Lead:</b> Bexley borough & Lewisham borough with SLAM and Oxleas and the CESEL team <b>Support:</b> Overprescribing Lead/Lambeth borough

Clinical Area	Outcomes	Rationale for area	Impact anticipated from this work	Timescale for completion – updated in September 2023	Lead organisation and supporting (where required)
Bone diseases	Guidance for the management of osteoporosis	No treatment pathway is currently in place and this is an area where frequent queries arise. This is also an area where there are inequalities in the management of patients (e.g. male osteoporosis).	<ul style="list-style-type: none"> <li>Consistent treatment pathway for SEL with advice on product choice.</li> <li>Educational resource for primary care on treatments to try before referral to specialists.</li> </ul>	December 2023 (previously September 2023)	<b>Lead:</b> Lambeth borough /GSTT <b>Support:</b> Bexley borough
Nutrition – use of vitamins post bariatric surgery	Guidance on the use of vitamin products in people post bariatric surgery	There is currently no local guidance in this area. There are frequent queries on this topic given the national self-care agenda.	<ul style="list-style-type: none"> <li>Clarity on prescribing arrangements in this area</li> <li>Consistent guidance for healthcare professionals to follow</li> <li>Education resource for primary care</li> </ul>	December 2023 (previously July 2023)	<b>Lead:</b> Bromley borough /KCH <b>Support:</b> Southwark borough/ Prescribing Support dietetic team for SEL
Developing shared care agreements/ transfer of prescribing/GP for new drugs presented to the IMOC	Agreements will be developed once status of drug agreed as “amber 3” via formulary submission/decision at IMOC. Each lead borough will follow the SEL process for developing shared care.	Patient safety / best practice To ensure that if a treatment is agreed, effective advice is in place for all clinicians who may prescribe. Drafts to be developed collaboratively between the lead borough and Trust.	Safer prescribing and clearly set out monitoring requirements for medicines considered suitable for shared care.	Determined with application process.	Responsibility for developing shared care is with the Trust making the request with support from the Lead borough. Responsibility for primary care consultation on drafts will be on a rotational basis by all 6 boroughs.

Existing IMOC guidelines due for review in 2023/24 – note: some are overdue for review due to COVID-19 pressures over the last 2 years.

Guideline	Lead/support organisations in SEL	Expiry date
Treatment of Wet Age-Related Macular Degeneration, Diabetic Macular Oedema, Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion	Greenwich/KCH (Southwark supporting) <i>Review underway</i>	Apr-19
SEL Pen needles fact sheet & patient letter template	Diabetes sub-group of SEL IMOC	Jun-19
Shared care prescribing guideline somatropin (recombinant growth hormone - rGH) for the treatment of Growth hormone deficiency, Turner syndrome, Chronic renal insufficiency, Prader-Willi syndrome, Small for gestational age and Short stature homeobox-containing gene (SHOX) deficiencies in paediatrics	KCH/Lambeth	Oct-19
Dermatology Specials fact sheets: (i) Beclometasone dipropionate; (ii) clobetasol propionate (iii) Lactic acid in Diprobace cream (iv) Monobenzone in cetomacrogol	Dermatology sub-group	Dec-19
South East London Chronic Open Angle Glaucoma and Ocular Hypertension Treatment Pathway	Led by GSTT, supported by ophthalmology sub-group	Jan-20
Actions for primary care on the valproate pregnancy prevention programme	KCHfT/Southwark <i>Will transfer to Medicines Safety Network</i>	Mar-20
South East London Pathway for the Management of Papulopustular Rosacea	Led by GSTT/Dermatology sub-group <i>Review underway via dermatology sub-group</i>	May-20
NHSE Low Priority products – <a href="#">various resources</a>	NHSE POMs/Self-care sub group	May-20
South East London pathway for the management of anal fissure	GSTT	May-20
Management of motor symptoms in people with Parkinson's with motor complications – opicapone place in therapy	KCHfT	Jul-20
South East London Adult Hyperhidrosis treatment pathway for primary care	GSTT/Dermatology sub-group of SEL IMOC <i>Review underway via dermatology sub-group</i>	Aug-20
Pathway for the pharmacological management of excessive daytime sleepiness due to narcolepsy and associated resource documents	GSTT (Sleep centre) <i>Review underway via the Sleep Centre</i>	Aug-20
Shared care guideline: Cinacalcet in the Treatment of Secondary Hyperparathyroidism in Adult End-Stage Renal Disease (ESRD) Patient Established on Dialysis Therapy	KCHfT/Greenwich Borough	Sep-20
Cinacalcet for the treatment of Secondary Hyperparathyroidism in Adult End-Stage Renal Disease (ESRD) Patients Established on Dialysis Therapy Shared Care Prescribing Guideline	KCHfT/Greenwich Borough	Sep-20
Shared care prescribing guideline Zonisamide for the treatment of epilepsy in adults	KCHfT/Southwark Borough	Oct-20
Shared care guideline: Nebulised mucolytic and antibiotic solutions for the treatment of Cystic Fibrosis in existing paediatric patients only	KCHfT/ Bromley Borough	Nov-20
Urticaria Treatment Pathway- Including naltrexone, danazol and doxepin GP info sheet (shared care)	Led by GSTT/Southwark via Dermatology sub-group <i>Review underway via dermatology sub-group</i>	Dec-20
Guide for primary care on the off-label use of medicines in the Oral Medicine Clinics in South East London	GSTT	Jan-21
South East London Clinical Guidance for the Management of Diabetes in Ramadan for Healthcare Professionals in Primary Care	Diabetes sub-group of SEL IMOC	Mar-21

Guideline	Lead/support organisations in SEL	Expiry date
South East London Pharmacological Management of Adult Non-Cancer Chronic Pain in Primary Care	Lewisham Borough <i>Review underway via short life working group</i>	Mar-21
South East London (SEL) Integrated Guideline for the Management of Allergic Rhinitis (AR)	GSTT <i>On hold as the Acute Provider Collaborative (APC) network is developing guidance</i>	Jun-21
Testosterone gel or sachets for the treatment of low sex drive in the menopause leaflet	GSTT	Jun-21
Guidance on options for the pharmacological management of hypersalivation in adult neurology patients (patients aged 18 and over)	GSTT	Sep-21
South East London glucagon-like peptide (GLP-1) analogue pathway for adults aged 18 years and over with Type 2 Diabetes Mellitus (T2DM) - Interim pathway to support care during the COVID-19 pandemic	Diabetes sub-group <i>Review complete – awaiting final documentation</i>	Nov-21
Shared care prescribing guideline Immunomodulatory Drugs: Azathioprine, Hydroxychloroquine, Leflunomide, Methotrexate, Mycophenolate and Sulfasalazine for the treatment of autoimmune rheumatic diseases in children (≤ 18 years of age)	Greenwich/Lewisham Borough <i>Review underway</i>	Jan-22
SEL Overactive Bladder (OAB) Care Pathway for adults in primary care	Bexley borough <i>On hold as the APC network is developing guidance</i>	Feb-22
Pharmacological Management of Restless Legs Syndrome (RLS) or Periodic Limb Movement Disorder (PLMD)	GSTT	Feb-22
South East London integrated guideline for the management of asthma in adults (18 years old and over)	Respiratory sub-group <i>On hold - London wide work underway</i>	Mar-22
Restless Leg Syndrome (RLS) – Information for GPs	GSTT	Mar-22
South East London Interface Prescribing Policy and NHS/Private Interface Prescribing Guide	Bexley Borough <i>On hold - London wide work underway</i>	Mar-22
Integrated Medication Guidelines for the use of Donepezil, Galantamine, Rivastigmine and Memantine in Dementia (Shared Care Prescribing Guideline)	SLaM/Bexley borough	Mar-22
South East London Integrated Guideline for the Management of Chronic Obstructive Pulmonary Disease	Respiratory sub-group	Apr-22
Atopic Dermatitis Dupilumab Treatment Pathway	Dermatology sub-group <i>Review underway via dermatology sub-group</i>	Jun-22
Interim arrangement for prescribing, monitoring and administration of Denosumab (Prolia®) in primary care for the prevention of osteoporotic fractures during the COVID-19 pandemic	GSTT/Bromley & Lambeth Boroughs <i>Review underway via short life working group</i>	Jun-22
South East London guideline for the investigation and management of Immune Thrombocytopenia (ITP) in adult patients over 18 years old	ITP pathway Group <i>Review underway via ITP sub-group</i>	Jul-22
SEL Irritable bowel syndrome pathway for adults	Greenwich Borough <i>Review underway</i>	Jul-22
Pharmacological management of refractory neuropathic pain in adults – GP Information Sheet	GSTT	Jul-22
SEL STOMP and STAMP Guidance SEL	Greenwich Borough	Jul-22

Guideline	Lead/support organisations in SEL	Expiry date
South East London Clinical Guideline for the Management of Vitamin D Deficiency in ADULTS (including pregnancy and breastfeeding) & Patient Information Leaflet	Greenwich Borough <i>Review underway</i>	Jul-22
South East London Clinical Guidance for the Management of Vitamin D Deficiency and Insufficiency in Children up to the age of 18 years - excluding neonates in Neonatal Units	Greenwich Borough <i>Review underway</i>	Jul-22
Shared care prescribing guideline Mycophenolate Mofetil for the prevention of Organ Rejection in Adult Liver Transplant Recipients in existing patients only (i.e. those already being prescribed this drug in primary care)	KCHfT/Lewisham borough	Jul-22
Shared care prescribing guideline: Continuation of Prograf™ (tacrolimus immediate release {IR}) for the prevention of organ rejection in ADULT liver transplant recipients in existing patients only (i.e. those already being prescribed this drug in primary care)	KCHfT/Lewisham borough	Jul-22
Switching from Concerta XL™ (methylphenidate) modified release tablets to Delmosart™ prolonged-release tablets	SLaM/Lambeth Borough	Aug-22
Switching from Concerta XL™ (methylphenidate) modified release tablets to Xenidate XL™ prolonged-release tablets	SLaM/Lambeth Borough	Aug-22
Shared care prescribing guideline for the prescribing and monitoring of non-biological Immunomodulatory drugs in dermatology, gastroenterology and autoimmune hepatitis, neurology, ophthalmology, oral medicine, respiratory and rheumatology in adults	Short life working group led by KCHfT/ Lambeth Borough	Sep-22
Shared care guideline: APO-go® (Apomorphine) for the treatment of Parkinson's in adults	KCHfT /Bromley Borough <i>Review underway</i>	Oct-22
South East London Emollient Guidance for Adults and Children & Patient Information Leaflet	Dermatology sub-group <i>Review underway via dermatology sub-group</i>	Oct-22
South East London pathway for the pharmacological management of gastroparesis initiated in secondary care	GSTT	Oct-22
Reconciliation of Hospital Prescribed and Supplied Medicines in Primary Care Implementation Pack	TBC	Oct-22
GP Information sheet - Request to continue prescribing of lacosamide in primary care for an adult patient	KCHfT/Southwark Borough	Oct-22
Guidance for prescribing melatonin for sleep disorders in paediatrics (children and adolescents) in South East London	Evelina/Greenwich Borough	Oct-22
Perampanel initiation and transfer of prescribing	KCHfT/Southwark Borough	Oct-22
GP Information sheet: Request to continue prescribing of tiagabine in adults in primary care	KCHfT/Southwark Borough	Oct-22
South East London guidance for managing erectile dysfunction (ED) in primary and secondary care	GSTT/Bexley Borough <i>On hold as the APC network is developing guidance</i>	Dec-22
<a href="#">Various CVD related guidelines</a>	CVD sub-group of SEL IMOC	Various review dates
Constipation management guidance (adults)	Greenwich	Apr-23

## South East London Integrated Medicines Optimisation Committee - sub-groups

